Literature DB >> 16938314

TNFalpha-induced cytoprotection requires the production of free radicals within mitochondria in C2C12 myotubes.

Lydia Lacerda1, Robert M Smith, Lionel Opie, Sandrine Lecour.   

Abstract

We previously reported that tumour necrosis factor alpha (TNFalpha) can mimic classic ischemic preconditioning (IPC) in both cells and heart. However, the signalling pathways involved remain incompletely understood. One potential protective pathway could be TNFalpha-induced reactive oxygen species (ROS). We hypothesized that TNFalpha cytoprotection occurs through the generation of ROS which originate within the mitochondria. C(2)C(12) myotubes were preconditioned with either a short period of hypoxia (IPC) or a low concentration of TNFalpha (0.5 ng/ml) prior to a simulated ischemic insult. ROS generation was evaluated on cells stained with dichlorofluorescin diacetate (DCFH-DA) by flow cytometry. The source of TNFalpha-induced ROS was examined with Mitotracker Red CM-H(2)XRos. The bioenergetics of the mitochondria were evaluated by investigation of the respiratory parameters and the inner mitochondrial membrane potential. Pretreatment with TNFalpha improved cell viability compared with the simulated ischemic control (TNFalpha: 75 +/- 1% versus 34 +/- 1% for the control: p<0.001). The ROS scavenger, N-2-mercaptopropionyl-glycine (MPG), reduced the viability of TNFalpha-stimulated cells to 15 +/- 1% (p<0.001 versus TNFalpha). Similar results were obtained with IPC. TNFalpha stimulation increased ROS production mainly in the mitochondria, and this increase was abolished in the presence of MPG. Addition of TNFalpha to the cells increased State 2 respiration and modestly depolarised the membrane potential prior to the ischemic insult. In conclusion, TNFalpha-induced ROS generation can occur within the mitochondria, resulting in temporal mitochondrial perturbations which may initiate the cytoprotective effect of TNFalpha.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16938314     DOI: 10.1016/j.lfs.2006.07.020

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  7 in total

1.  TNFα protects cardiac mitochondria independently of its cell surface receptors.

Authors:  Lydia Lacerda; Joy McCarthy; Shazia F K Mungly; Edward G Lynn; Michael N Sack; Lionel H Opie; Sandrine Lecour
Journal:  Basic Res Cardiol       Date:  2010-08-01       Impact factor: 17.165

2.  Protective role of normothermic, hyperthermic and estrogen preconditioning and pretreatment on tumour necrosis factor-alpha-induced damage.

Authors:  Jasbir S Juggi; Lamia J Hoteit; Fawzi A Babiker; Shaji Joseph; Abu Salim Mustafa
Journal:  Exp Clin Cardiol       Date:  2011

3.  Focal cerebral ischemia and mitochondrial dysfunction in the TNFα-transgenic rat.

Authors:  Jignesh D Pandya; Patrick G Sullivan; L Creed Pettigrew
Journal:  Brain Res       Date:  2011-02-26       Impact factor: 3.252

4.  The protective effects of 17beta-estradiol against ischemia-reperfusion injury and its effect on pacing postconditioning protection to the heart.

Authors:  Fawzi A Babiker; Shaji Joseph; Jasbir Juggi
Journal:  J Physiol Biochem       Date:  2013-09-14       Impact factor: 4.158

5.  SS-31 attenuates TNF-α induced cytokine release from C2C12 myotubes.

Authors:  Adam P Lightfoot; Giorgos K Sakellariou; Gareth A Nye; Francis McArdle; Malcolm J Jackson; Richard D Griffiths; Anne McArdle
Journal:  Redox Biol       Date:  2015-08-10       Impact factor: 11.799

6.  Sex Differences of Human Cardiac Progenitor Cells in the Biological Response to TNF-α Treatment.

Authors:  Elisabetta Straface; Lucrezia Gambardella; Francesca Pagano; Francesco Angelini; Barbara Ascione; Rosa Vona; Elena De Falco; Elena Cavarretta; Raffaele La Russa; Walter Malorni; Giacomo Frati; Isotta Chimenti
Journal:  Stem Cells Int       Date:  2017-09-17       Impact factor: 5.443

7.  Nuclear Genome-Encoded Long Noncoding RNAs and Mitochondrial Damage in Diabetic Retinopathy.

Authors:  Ghulam Mohammad; Renu A Kowluru
Journal:  Cells       Date:  2021-11-23       Impact factor: 6.600

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.